Melior Discovery, Inc. announced today that it has signed an option agreement that provides Pfizer Inc the exclusive right to negotiate a license to MLR-1023, Melior’s drug candidate for Type II diabetes. In exchange, Pfizer agreed to make an undisclosed payment to Melior and provide access to certain data it owns related to MLR-1023. In [...]
Continue reading " Melior Signs Option Agreement with Pfizer "